Why regulators want to ban a key ingredient in kratom, a popular herbal supplement

Key Concepts

• Kratom
• Mitragynine
• 7-hydroxymitragynine (7-oh)
• Opioid withdrawal
• Regulation of herbal supplements
• Synthetic kratom compounds
• Alkaloids
• Respiratory depression

Kratom: Traditional Use and Modern Popularity

For centuries, kratom, a tree native to Southeast Asia, particularly Indonesia, has been utilized by local populations as a home remedy. Its traditional uses include soothing nerves, easing pain (analgesic properties), and treating indigestion. It is typically brewed into teas and viewed by indigenous communities as a general cure for various ailments.

Kratom in the United States: Opioid Crisis and Unregulated Market

Kratom's popularity has surged in the United States, largely driven by its perceived efficacy in alleviating anxiety and, more significantly, aiding in the management of opioid withdrawal. Individuals struggling with opioid addiction have turned to kratom as a less harmful alternative to street drugs or a way to wean themselves off prescription painkillers. These products are readily available in smoke shops and gas stations.

Challenges in Regulating Kratom

The primary challenge in regulating kratom products stems from the inherent difficulty in understanding the precise scientific mechanisms of how substances interact with the human body. Dosing limits are poorly understood due to individual physiological differences. Unlike pharmaceuticals, which undergo extensive clinical trials and scientific testing to establish safe and lethal dosages, kratom lacks this rigorous scientific backing.

Kratom Products: Natural vs. Synthetic and Concentrated Forms

The kratom market encompasses several categories of products:

• Traditional Kratom Tea: Similar to the product consumed for centuries in Indonesia, often found in kava shops.
• Concentrated Mitragynine Products: These products contain highly concentrated forms of mitragynine, the primary active ingredient in kratom. The effects of these concentrated forms are largely unknown, yet they are widely available online and across many states.
• Synthetic Versions and 7-hydroxymitragynine (7-oh): A significant concern is the presence of synthetic versions of kratom compounds, particularly 7-hydroxymitragynine (7-oh). This alkaloid, naturally present in kratom at very low doses, mimics opioids in its interaction with the brain and can contribute to respiratory depression, a primary cause of opioid overdose deaths. U.S. officials and some states, including Florida, have sought to restrict or remove 7-oh from the market due to its potential for abuse and addiction.

Distinguishing Between Kratom and its Derivatives

There is a consensus, even within the kratom industry, that 7-oh should not be offered as a product. The U.S. federal government and some state governments have made a distinction between the natural kratom product and its synthetic derivatives, a distinction considered wise for regulatory purposes. While reasonable minds may differ on the best approach to regulating other kratom products, the urgency is evident as people are using these substances in ways akin to pharmaceuticals without adequate understanding of the risks.

Potential Benefits and Risks

While acknowledging the potential benefits some individuals experience with kratom, particularly in managing opioid withdrawal, the transcript highlights the inherent dangers associated with its unregulated nature and the increasing concentration of active compounds. The widespread availability and use of kratom suggest that if it were as dangerous as opioids, the observed harm would be significantly greater. However, the lack of comprehensive scientific data and established dosing guidelines leaves users vulnerable.

Conclusion

Kratom, a plant with a long history of traditional use in Southeast Asia, has gained significant traction in the U.S. as a remedy for anxiety and opioid withdrawal. However, its poorly regulated status, coupled with the emergence of highly concentrated and synthetic versions like 7-hydroxymitragynine, presents substantial public health concerns. The lack of rigorous scientific study on dosing and long-term effects, combined with industry incentives to produce more potent iterations, necessitates careful consideration and regulation to mitigate potential risks while acknowledging the perceived benefits for some users.